Shockwave Medical HOME / ABOUT / PRESS RELEASES Press Releases Shockwave Medical Enrolls First Patient in Disrupt BTK II Study for Long, Calcified, Below the Knee Lesions Global Post-Market Study Will Assess Long-Term Benefit of Peripheral IVL on the Most Challenging Calcified Lesions, Including Patients with Critical Limb Ischemia SANTA CLARA, Calif., Nov. 22, 2021 (GLOBE NEWSWIRE) -- Shockwave Medical, Inc. (NASDAQ: SWAV), a pioneer in the development of Intravascular Lithotripsy (IVL) to treat severely calcified cardiovascular disease, today announced the start of the Disrupt BTK II post-market study to assess the safety, effectiveness and optimal clinical use of the Shockwave Peripheral IVL System for the treatment of calcified peripheral lesions below the knee (BTK), including some of the most challenging patients with critical limb ischemia (CLI). Disrupt BTK II is a post-market, prospective, multicenter, single-arm study led by Ehrin Armstrong, M.D., Medical Director and Interventional Cardiologist, Adventist Heart & Vascular Institute, and Venita Chandra, M.D., Vascular Surgeon and Clinical Associate Professor, Division of Vascular Surgery, Stanford Health Care. The study is expected to enroll 250 patients across 40 sites globally that will be followed for two years to assess the long-term durability of IVL in this difficult to treat patient population. The first Disrupt BTK II patient was enrolled at Midwest Cardiovascular Research Foundation by Dr. Nicolas Shammas. “Patients with severely calcified, diffuse below the knee disease, and especially those with critical limb ischemia, are often in severe pain with limited treatment options to achieve adequate arterial revascularization. The unmet clinical need for this population is extremely high,” said Dr. Armstrong. “Disrupt BTK II will further evaluate how IVL may be optimally used to treat patients who have historically been excluded from most endovascular treatment trials.” The primary effectiveness endpoint of Disrupt BTK II is procedural success, defined as ≤50 percent residual stenosis for all treated target lesions without serious angiographic complications (flow-limiting dissection, perforation, distal embolization, or acute vessel closure), as assessed by an independent angiographic core lab. The study will assess the absence of major adverse limb events (MALE) within 30 days of the index procedure as a primary safety endpoint. “More and more patients with CLI also present with end-stage renal disease, advanced diabetes, or other comorbidities that impact their overall health and our ability to effectively treat their CLI,” said Dr. Chandra. “We already know that IVL can reduce significant dissection as well as reduce the need for provisional stenting over conventional PTA in peripheral vessel beds, but what makes Disrupt BTK II even more exciting is that we are now isolating the treatment effect to get a clearer picture about what role IVL can offer as a definitive therapy for these very complex patients.” About Shockwave Medical, Inc. Shockwave is focused on developing and commercializing products intended to transform the way calcified cardiovascular disease is treated. Shockwave aims to establish a new standard of care for the interventional treatment of atherosclerotic cardiovascular disease through differentiated and proprietary local delivery of sonic pressure waves for the treatment of calcified plaque, which the company refers to as Intravascular Lithotripsy (IVL). IVL is a minimally invasive, easy-to-use and safe way to significantly improve patient outcomes. To view an animation of the IVL procedure and for more information, visit www.shockwavemedical.com. Forward-Looking Statements This press release contains statements relating to our expectations, projections, beliefs, and prospects, which are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. In some cases, you can identify these statements by forward-looking words such as “may,” “might,” “will,” “should,” “expects,” “plans,” “anticipates,” “believes,” “estimates,” “predicts,” “potential” or “continue,” and similar expressions, and the negative of these terms. You are cautioned not to place undue reliance on these forward-looking statements. Forward-looking statements are only predictions based on our current expectations, estimates, and assumptions, valid only as of the date they are made, and subject to risks and uncertainties, some of which we are not currently aware. Important factors that could cause our actual results and financial condition to differ materially from those indicated in the forward-looking statements include, among others: the impact of the COVID-19 pandemic on our operations, financial results, and liquidity and capital resources, including the impact on our sales, expenses, supply chain, manufacturing, research and development activities, clinical trials, and employees; our ability to develop, manufacture, obtain and maintain regulatory approvals for, market and sell, our products; our expected future growth, including the size and growth potential of the markets for our products; our ability to obtain coverage and reimbursement for procedures performed using our products; our ability to scale our organizational culture; the impact of the development, regulatory approval, efficacy and commercialization of competing products; the loss of key scientific or management personnel; our ability to develop and maintain our corporate infrastructure, including our internal controls; our financial performance and capital requirements; and our ability to obtain and maintain intellectual property protection for our products, as well as our ability to operate our business without infringing the intellectual property rights of others. These factors, as well as others, are discussed in our filings with the Securities and Exchange Commission (SEC), including in Part I, Item IA - Risk Factors in our most recent Annual Report on Form 10-K filed with the SEC, and in our other periodic and other reports filed with the SEC. Except to the extent required by law, we do not undertake to update any of these forward-looking statements after the date hereof to conform these statements to actual results or revised expectations Media Contact: Scott Shadiow +1.317.432.9210 sshadiow@shockwavemedical.com Investor Contact: Debbie Kaster dkaster@shockwavemedical.com Source: Shockwave Medical, Inc. Share this page: LinkedIn Twitter Facebook See all press releases Ready to Make Waves with Shockwave IVL? FIRST NAME* LAST NAME* INSTITUTION* EMAIL* COUNTRY* PLEASE SELECT AFGHANISTAN ÅLAND ISLANDS ALBANIA ALGERIA AMERICAN SAMOA ANDORRA ANGOLA ANGUILLA ANTARCTICA ANTIGUA AND BARBUDA ARGENTINA ARMENIA ARUBA AUSTRALIA AUSTRIA AZERBAIJAN BAHAMAS BAHRAIN BANGLADESH BARBADOS BELARUS BELGIUM BELIZE BENIN BERMUDA BHUTAN BOLIVIA (PLURINATIONAL STATE OF) BONAIRE, SINT EUSTATIUS AND SABA BOSNIA AND HERZEGOVINA BOTSWANA BOUVET ISLAND BRAZIL BRITISH INDIAN OCEAN TERRITORY UNITED STATES MINOR OUTLYING ISLANDS VIRGIN ISLANDS (BRITISH) VIRGIN ISLANDS (U.S.) BRUNEI DARUSSALAM BULGARIA BURKINA FASO BURUNDI CABO VERDE CAMBODIA CAMEROON CANADA CAYMAN ISLANDS CENTRAL AFRICAN REPUBLIC CHAD CHILE CHINA CHRISTMAS ISLAND COCOS (KEELING) ISLANDS COLOMBIA COMOROS CONGO CONGO (DEMOCRATIC REPUBLIC OF THE) COOK ISLANDS COSTA RICA CROATIA CUBA CURAÇAO CYPRUS CZECH REPUBLIC DENMARK DJIBOUTI DOMINICA DOMINICAN REPUBLIC ECUADOR EGYPT EL SALVADOR EQUATORIAL GUINEA ERITREA ESTONIA ETHIOPIA FALKLAND ISLANDS (MALVINAS) FAROE ISLANDS FIJI FINLAND FRANCE FRENCH GUIANA FRENCH POLYNESIA FRENCH SOUTHERN TERRITORIES GABON GAMBIA GEORGIA GERMANY GHANA GIBRALTAR GREECE GREENLAND GRENADA GUADELOUPE GUAM GUATEMALA GUERNSEY GUINEA GUINEA-BISSAU GUYANA HAITI HEARD ISLAND AND MCDONALD ISLANDS HOLY SEE HONG KONG HONDURAS HUNGARY ICELAND INDONESIA INDIA IRELAND CÔTE D'IVOIRE IRAN (ISLAMIC REPUBLIC OF) IRAQ ISLE OF MAN ISRAEL ITALY JAPAN JAMAICA JERSEY JORDAN KAZAKHSTAN KENYA KIRIBATI KUWAIT KYRGYZSTAN LAO PEOPLE'S DEMOCRATIC REPUBLIC LATVIA LEBANON LESOTHO LIBERIA LIBYA LIECHTENSTEIN LUXEMBOURG LITHUANIA MACAO MACEDONIA (THE FORMER YUGOSLAV REPUBLIC OF) MADAGASCAR MALAWI MALAYSIA MALDIVES MALI MALTA MARSHALL ISLANDS MARTINIQUE MAURITANIA MAURITIUS MAYOTTE MEXICO MICRONESIA (FEDERATED STATES OF) MOLDOVA (REPUBLIC OF) MONACO MONGOLIA MONTENEGRO MONTSERRAT MOROCCO MOZAMBIQUE MYANMAR NAMIBIA NAURU NEPAL NETHERLANDS NEW CALEDONIA NEW ZEALAND NICARAGUA NIGER NIGERIA NIUE NORFOLK ISLAND KOREA (DEMOCRATIC PEOPLE'S REPUBLIC OF) NORTHERN MARIANA ISLANDS NORWAY OMAN PAKISTAN PALAU PALESTINE, STATE OF PANAMA PAPUA NEW GUINEA PARAGUAY PERU PHILIPPINES PITCAIRN PORTUGAL POLAND PUERTO RICO QATAR REPUBLIC OF KOSOVO RÉUNION ROMANIA RUSSIA RWANDA SAINT BARTHÉLEMY SAINT HELENA, ASCENSION AND TRISTAN DA CUNHA SAINT KITTS AND NEVIS SAINT LUCIA SAINT MARTIN (FRENCH PART) SAINT PIERRE AND MIQUELON SAINT VINCENT AND THE GRENADINES SAMOA SAN MARINO SAO TOME AND PRINCIPE SAUDI ARABIA SENEGAL SERBIA SEYCHELLES SIERRA LEONE SINGAPORE SINT MAARTEN (DUTCH PART) SLOVAKIA SLOVENIA SOLOMON ISLANDS SOMALIA SOUTH AFRICA SOUTH GEORGIA AND THE SOUTH SANDWICH ISLANDS KOREA (REPUBLIC OF) SOUTH SUDAN SPAIN SRI LANKA SUDAN SURINAME SVALBARD AND JAN MAYEN SWAZILAND SWEDEN SWITZERLAND SYRIAN ARAB REPUBLIC TAIWAN TAJIKISTAN TANZANIA, UNITED REPUBLIC OF THAILAND TIMOR-LESTE TOGO TOKELAU TONGA TRINIDAD AND TOBAGO TUNISIA TURKEY TURKMENISTAN TURKS AND CAICOS ISLANDS TUVALU UGANDA UKRAINE UNITED ARAB EMIRATES UNITED KINGDOM UNITED STATES URUGUAY UZBEKISTAN VANUATU VENEZUELA (BOLIVARIAN REPUBLIC OF) VIET NAM WALLIS AND FUTUNA WESTERN SAHARA YEMEN ZAMBIA ZIMBABWE CITY/STATE PROFESSION* PLEASE SELECT ADMINISTRATOR ANALYST ANGIOLOGIST INDUSTRY INTERVENTIONAL CARDIOLOGIST INTERVENTIONAL RADIOLOGIST MEDIA NURSE/TECHNICIAN RADIOLOGIST VASCULAR SURGEON PATIENT AREAS OF INTEREST* CORONARY EVAR/TEVAR TAVI/TAVR PERIPHERAL MESSAGE Shockwave Medical is committed to protecting and respecting your privacy, and we’ll only use your personal information to administer your account and to provide the products and services you requested from us. From time to time, we would like to contact you about our products and services, as well as other content that may be of interest to you. If you consent to us contacting you for this purpose, please tick below to say how you would like us to contact you: I AGREE TO RECEIVE OTHER COMMUNICATIONS FROM SHOCKWAVE MEDICAL. You can unsubscribe from these communications at any time. For more information on how to unsubscribe, our privacy practices, and how we are committed to protecting and respecting your privacy, please review our Privacy Policy. I AGREE TO ALLOW SHOCKWAVE MEDICAL TO STORE AND PROCESS MY PERSONAL DATA.* In order to provide you the content requested, we need to store and process your personal data. If you consent to us storing your personal data for this purpose, please tick the checkbox. Shockwave Medical Corporate Headquarters 5403 Betsy Ross Drive Santa Clara, CA 95054 United States 1-877-77-LITHO (775-4846) Follow us Prior to use, please reference the Instructions for Use for more information on indications, contraindications, warnings, precautions and adverse events. Privacy Policy Do Not Sell My Personal Information Patents © 2021 Shockwave Medical Inc. All rights reserved. By clicking “Accept All Cookies”, you agree to the storing of cookies on your device to enhance site navigation, analyze site usage, and assist in our marketing efforts. Cookies Settings Accept All Cookies